Unusual Put Options Activity in Merck Raises Questions About Stock Valuation
Merck & Co., Inc. (MRK) has experienced a notable surge in its stock price, rising by 10.85% to $149.83 following the release of strong Q2 earnings. However, this positive momentum is contrasted by an unusual spike in put options trading at a significantly lower strike price, raising questions about the stock's valuation.
On August 4, Merck reported strong revenue growth, particularly driven by its oncology drug portfolio. The company also announced successful results from a stage IV melanoma drug combination trial with Moderna, contributing to the stock's recent rise. Despite this, the trading of over 7,000 put contracts at a $135 strike price—almost 10% below the current price—has sparked speculation among investors.
For Your Trading Desk
Sponsor Spike Success.
This unusual options activity, which is nearly 70 times the previous number of put contracts outstanding, suggests that some investors may be betting against the stock. Analysts have mixed views on Merck's valuation, with the average price target from 28 analysts surveyed being $137.73, indicating a potential decline from current levels.
Earnings per share (EPS) for Merck are projected to drop significantly this year, leading to a high expected price-to-earnings (P/E) ratio of over 54x. However, some analysts argue that this assessment may overlook the impact of one-time acquisition charges that have depressed EPS estimates. Without these charges, normalized EPS could be much higher, leading to a more favorable forward P/E ratio.
The potential for a dividend increase next quarter, consistent with Merck's historical performance, adds another layer to the valuation discussion. If the dividend rises to $3.63, the price target could drop to $123.47, suggesting a significant downside risk.
In conclusion, while the unusual put options activity indicates some investor skepticism about Merck's stock price, the company's strong fundamentals and potential for future growth may suggest that the stock is not as overvalued as some believe. Investors should carefully consider their positions, particularly in light of the current market dynamics.




